Page 81 - Felix Nipkow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Felix nipkow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Felix Nipkow Today - Breaking & Trending Today

Can the Alien franchise be saved?

Reports of another Alien installment remind us that the franchise has been lost in space since James Cameron's classic 1986 sequel ....

United States , Ridley Scott , David Fincher , Disney Fox , Dwayne Hicks , Mike Marsland Wireimage Getty , Damon Lindelof , James Cameron , Michael Fassbender , Neil Blomkamp , Easttownactress Cailee Spaeny , Sigourney Weaver , Noah Hawley , Joss Whedon , John Logan , Evil Dead , Dont Breathe , Sunset Boulevard , Getty Images , Close Encounters Of The Third Kind , Best Actress Oscar , Jean Pierre Jeunet , City Of Lost Children , Buffy The Vampire Slayer , Frankenstein Meets The Wolf Man , Century Fox ,

BBCNEWS Sportsday June 4, 2024 18:43:00

Have been 0k, i analyse the performances, they have been ok, but we have had costly moments in the games where we should have taken points, three points, and a number of times where we haven t taken any. so today we gave nothing to much away, which is important, and you have to show that spirit and that resilience. you see the guys giving everything, so i was really pleased in that way. i giving everything, so i was really pleased in that way. giving everything, so i was really pleased in that way. i think we are in a very good pleased in that way. i think we are in a very good position pleased in that way. i think we are in a very good position in - pleased in that way. i think we are in a very good position in many . in a very good position in many ways, in a very good position in many ways, performance wise. points and so on ways, performance wise. points and so on but ways, performance wise. points and so on but we ways, performance wise. points and so on. but we nee ....

We Haven T , Game Layers , Vi 0 , Winning Run , Premier League Scores ,

FDA Approves Expanded Indication for Telix's Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy

MELBOURNE, Australia, March 16, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom lutetium-177 (177Lu) PSMA-directed therapy is indicated.[1] The label expansion means Illuccix is now approved in the U.S. to identify and select patients who are candidates for the only FDA-approved prostate-specific membrane antigen (PSMA)- directed radioligand therapy (Pluvicto),[2] providing doctors with critical information to guide patient management and help optimise treatment outcomes. To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent.[3] As the only diagnostic agent for prostate cancer that combines the accuracy of gall ....

United States , United Kingdom , Kyahn Williamson , Kevin Richardson , Oliver Sartor , Telix Pharmaceuticals , Drug Administration , Tulane Cancer Center , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Health Canada , American Cancer Society , Pharmaceuticals Limited , United States Food , New Drug Application , Chief Executive Officer , Telix Americas , Medical Director , Telix Pharmaceuticals Limited , Emission Tomography , Computed Tomography , Cancer Society , Key Statistics , Prostate Cancer ,

Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU

MELBOURNE, Australia, March 14, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).1 The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud University Medical Centre (Netherlands), a ZIRCON Principal Investigator, at the 38th Annual European Association of Urology (EAU) Congress, on Saturday, 11 March 2023. Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice. New data presented: TLX250-CDx demonstrated a high degree of consistency between readers with a very high sensitivity (85.5%) and specificity (87.0%) overall, and 85.5% / 89.5% for small masses ....

United States , United Kingdom , Kyahn Williamson , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Radboud University Medical Centre Netherlands , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Radboud University Medical Centre , Annual European Association , Congress Office , About Telix Pharmaceuticals Limited , Telix Pharmaceuticals Limited , March 14 , 023 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , He Company Today Announces Additional Positive Results From Its Completed Pivotal Phase Iii Zircon Study Of Tlx250 Cdx 89zr Dfo Girentuximab In Clear Cell Renal Carcinoma Ccrcc Clinicaltrials Gov Identifier Nct03849118 1 The Were Featured Ina Quot Game Changing Oral Session Delivered By Professor Dr Peter Mulders Radboud University Medical Centre Netherlands , A Zircon Principal Investigator , T The 38th Annual European Association Of Urology Eau Congress , On Saturday ,

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 - 13 March 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a "Game Changing" oral session. Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice. In addition, presentations will report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer (ZiPUP study, ClinicalTrials.gov Identifier: NCT05046665); and a preclinical evaluation of a ....

Noord Brabant , United States , United Kingdom , Kyahn Williamson , Colin Hayward , Peter Mulders , European Association Of Urology , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , University Of Western Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Scientific Congress Office , Health Canada , Pharmaceuticals Limited , Annual European Association , Congress Office , Telix Chief Medical Officer , Professor Peter Mulders , Game Changing , Clinical Trials , Urothelial Cancer Patients , Western Australia , Telix Pharmaceuticals Limited ,